TY - JOUR
T1 - Collateral consequences of agricultural fungicides on pathogenic yeasts
T2 - A One Health perspective to tackle azole resistance
AU - Castelo-Branco, Débora
AU - Lockhart, Shawn R.
AU - Chen, Yee Chun
AU - Santos, Daniel Assis
AU - Hagen, Ferry
AU - Hawkins, Nichola Jane
AU - Lavergne, Rose Anne
AU - Meis, Jacques F.
AU - Le Pape, Patrice
AU - Rocha, Marcos Fabio Gadelha
AU - Sidrim, José Julio Costa
AU - Arendrup, Maiken
AU - Morio, Florent
N1 - Publisher Copyright:
© 2021 Wiley-VCH GmbH
PY - 2022
Y1 - 2022
N2 - Candida and Cryptococcus affect millions of people yearly, being responsible for a wide array of clinical presentations, including life-threatening diseases. Interestingly, most human pathogenic yeasts are not restricted to the clinical setting, as they are also ubiquitous in the environment. Recent studies raise concern regarding the potential impact of agricultural use of azoles on resistance to medical antifungals in yeasts, as previously outlined with Aspergillus fumigatus. Thus, we undertook a narrative review of the literature and provide lines of evidence suggesting that an alternative, environmental route of azole resistance, may develop in pathogenic yeasts, in addition to patient route. However, it warrants sound evidence to support that pathogenic yeasts cross border between plants, animals and humans and that environmental reservoirs may contribute to azole resistance in Candida or other yeasts for humans. As these possibilities could concern public health, we propose a road map for future studies under the One Health perspective.
AB - Candida and Cryptococcus affect millions of people yearly, being responsible for a wide array of clinical presentations, including life-threatening diseases. Interestingly, most human pathogenic yeasts are not restricted to the clinical setting, as they are also ubiquitous in the environment. Recent studies raise concern regarding the potential impact of agricultural use of azoles on resistance to medical antifungals in yeasts, as previously outlined with Aspergillus fumigatus. Thus, we undertook a narrative review of the literature and provide lines of evidence suggesting that an alternative, environmental route of azole resistance, may develop in pathogenic yeasts, in addition to patient route. However, it warrants sound evidence to support that pathogenic yeasts cross border between plants, animals and humans and that environmental reservoirs may contribute to azole resistance in Candida or other yeasts for humans. As these possibilities could concern public health, we propose a road map for future studies under the One Health perspective.
KW - antifungal resistance
KW - Candida spp.
KW - cross-resistance
KW - environmental fungicides
KW - medical antifungals
KW - One Health
U2 - 10.1111/myc.13404
DO - 10.1111/myc.13404
M3 - Review
C2 - 34821412
AN - SCOPUS:85120406058
VL - 65
SP - 303
EP - 311
JO - Mycoses
JF - Mycoses
SN - 0933-7407
IS - 3
ER -